Kim A. Connelly

FRACP, PhD, MBBS

Scientist

Biography

Dr. Kim Connelly is a Cardiologist and Scientist who is both nationally recognized as an expert in echocardiography, cardiovascular MRI and the impact of diabetes upon cardiac function and ventricular remodeling. His work has been recognized evident by winning the “Young Investigator of the Year Award” by the Canadian Cardiovascular Society, an Early Researcher Award in 2014, and a CIHR New Investigator award in 2014.

Dr. Connelly runs a basic research laboratory at the Keenan Research Centre at St. Michael’s Hospital where he focuses upon basic mechanisms of disease – primarily around the role of pathological extracellular matrix accumulation and the pro-sclerotic cytokine transforming growth factor beta, with a focus upon translating discoveries into therapies in humans. He developed the first hemodynamically validated model of diabetes induced HFpEF. He is the Director of the Krembil Stem Cell Facility at St. Michael’s Hospital and uses regenerative cell based therapies to improve cardiac and renal dysfunction as a result of diabetes. He has research support from the HSF of Canada, CIHR and CFI along with significant research support from the pharmaceutical industry. His work has been published in journals such as the NEJM, Circulation, Journal of the American college of Cardiology, Circulation Research, Diabetes, Cell Metabolism and Lancet Endocrinology and Diabetes.

His H index is 45, and I index of 140.

Dr Connelly is immediate past president of the Canadian Society of Cardiac Magnetic resonance imaging. He runs a translational imaging laboratory and uses hyperpolarized C13 metabolic imaging to understand metabolism in the human heart in real time, as well as CMR to understand the impact of exercise upon cardiac remodeling. He was senior author of the EMPA HEART study along with Dr Verma and Zinman to assess the mechanism by which the SGLT2i empagliflozin provided cardiac protection in patients with type 2 DM. Finally, he was past section lead of 2018 macrovascular complications section for the Diabetes Canada Clinical practice updates and is current chair of the Canadian Cardiovascular Society guidelines.

Recent Publications

  1. Adamo, M, Russo, G, Pagnesi, M, Pancaldi, E, Alessandrini, H, Andreas, M et al.. Prediction of Mortality and Heart Failure Hospitalization After Transcatheter Tricuspid Valve Interventions: Validation of TRISCORE. JACC Cardiovasc Interv. 2024;17 (7):859-870. doi: 10.1016/j.jcin.2024.02.013. PubMed PMID:38599688 .
  2. Dorian, D, Gustafson, D, Quinn, R, Bentley, RF, Dorian, P, Goodman, JM et al.. Exercise-Dependent Modulation of Immunological Response Pathways in Endurance Athletes With and Without Atrial Fibrillation. J Am Heart Assoc. 2024;13 (6):e033640. doi: 10.1161/JAHA.123.033640. PubMed PMID:38497478 PubMed Central PMC11009995.
  3. Vecchiarelli, E, Bentley, RF, Connelly, KA, Dorian, P, Yan, A, Mak, S et al.. Atrial fibrillation in middle-aged athletes: Impact on left atrial, ventricular and exercise performance. PLoS One. 2024;19 (3):e0294367. doi: 10.1371/journal.pone.0294367. PubMed PMID:38478534 PubMed Central PMC10936837.
  4. Russo, G, Hahn, RT, Alessandrini, H, Andreas, M, Badano, LP, Braun, D et al.. Effects of tricuspid transcatheter edge-to-edge repair on tricuspid annulus diameter - Data from the TriValve registry. Int J Cardiol. 2024; :131934. doi: 10.1016/j.ijcard.2024.131934. PubMed PMID:38437953 .
  5. Chin, K, Jiang, H, Steinberg, BE, Goldenberg, NM, Desjardins, JF, Kabir, G et al.. Bilateral Nephrectomy Impairs Cardiovascular Function and Cerebral Perfusion in a Rat Model of Acute Hemodilutional Anemia. J Appl Physiol (1985). 2024; :. doi: 10.1152/japplphysiol.00858.2023. PubMed PMID:38385183 .
  6. Cai, S, Haghbayan, H, Chan, KKW, Deva, DP, Jimenez-Juan, L, Connelly, KA et al.. Tissue mapping by cardiac magnetic resonance imaging for the prognostication of cardiac amyloidosis: A systematic review and meta-analysis. Int J Cardiol. 2024;403 :131892. doi: 10.1016/j.ijcard.2024.131892. PubMed PMID:38382853 .
  7. Ali, MU, Mancini, GBJ, Fitzpatrick-Lewis, D, Connelly, KA, O'Meara, E, Zieroth, S et al.. The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis. Cardiovasc Diabetol. 2024;23 (1):72. doi: 10.1186/s12933-024-02154-w. PubMed PMID:38360604 PubMed Central PMC10870515.
  8. Krishnaraj, A, Bakbak, E, Teoh, H, Pan, Y, Firoz, IN, Pandey, AK et al.. Vascular Regenerative Cell Deficiencies in South Asian Adults. J Am Coll Cardiol. 2024;83 (7):755-769. doi: 10.1016/j.jacc.2023.12.012. PubMed PMID:38355246 .
  9. Verma, R, Dhingra, NK, Connelly, KA. Obesity/cardiometabolic phenotype of heart failure with preserved ejection fraction: mechanisms to recent trials. Curr Opin Cardiol. 2024;39 (2):92-97. doi: 10.1097/HCO.0000000000001113. PubMed PMID:38294186 .
  10. Verma, S, Pandey, A, Pandey, AK, Butler, J, Lee, JS, Teoh, H et al.. Aldosterone and aldosterone synthase inhibitors in cardiorenal disease. Am J Physiol Heart Circ Physiol. 2024;326 (3):H670-H688. doi: 10.1152/ajpheart.00419.2023. PubMed PMID:38133623 .
Search PubMed

Affiliations & Other Activities

  • Director, Krembil Stem Cell Facility, St. Michael’s Hospital
  • Staff Cardiologist, Division of Cardiology, St. Michael’s Hospital
  • Member, Richard Lewar Center, University of Toronto
  • Cardiologist, Division of Cardiology, Sunnybrook Health Sciences Centre